Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInterest Coverage RatioInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

Taysha Gene Therapies (TSHA) Return on Equity (2022 - 2025)

Historic Return on Equity for Taysha Gene Therapies (TSHA) over the last 4 years, with Q3 2025 value amounting to 0.4%.

  • Taysha Gene Therapies' Return on Equity rose 4200.0% to 0.4% in Q3 2025 from the same period last year, while for Sep 2025 it was 0.4%, marking a year-over-year increase of 4200.0%. This contributed to the annual value of 1.16% for FY2024, which is 7900.0% up from last year.
  • As of Q3 2025, Taysha Gene Therapies' Return on Equity stood at 0.4%, which was up 4200.0% from 0.57% recorded in Q2 2025.
  • In the past 5 years, Taysha Gene Therapies' Return on Equity registered a high of 19.04% during Q1 2023, and its lowest value of 28.49% during Q4 2022.
  • Its 4-year average for Return on Equity is 1.17%, with a median of 0.87% in 2024.
  • Per our database at Business Quant, Taysha Gene Therapies' Return on Equity skyrocketed by 227700bps in 2023 and then tumbled by -202700bps in 2024.
  • Over the past 4 years, Taysha Gene Therapies' Return on Equity (Quarter) stood at 28.49% in 2022, then skyrocketed by 80bps to 5.72% in 2023, then soared by 82bps to 1.06% in 2024, then soared by 62bps to 0.4% in 2025.
  • Its Return on Equity stands at 0.4% for Q3 2025, versus 0.57% for Q2 2025 and 1.3% for Q1 2025.